Everything below concerns obesity research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-07. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
White blood cells defend against infections and are involved in the inflammatory response. A high white blood cell count, which is called leukocytosis, often occurs in infections, inflammation, and states of physiologic stress. It can also be caused by diseases that involve abnormal production of blood cells, such as myeloproliferative and lymphoproliferative disorders. A decreased white blood cell count, termed leukopenia, can lead to an increased risk of acquiring infections, and occurs in treatments like chemotherapy and radiation therapy and many conditions that inhibit the production of blood cells. Sepsis is associated with both leukocytosis and leukopenia. The total white blood cell count is usually reported in cells per microlitre of blood (/μL) or 109 cells per litre (× 109/L). In the white blood cell differential, the different types of white blood cells are identified and counted. The results are reported as a percentage and as an absolute number per unit volume. Five types of white blood cells—neutrophils, lymphocytes, monocytes, eosinophils, and basophils—are typically measured. Some instruments report the number of immature granulocytes, which is a classification consisting of precursors of neutrophils; specifically, promyelocytes, myelocytes and metamyelocytes. Other cell types are reported if they are identified in the manual differential. Differential results are useful in diagnosing and monitoring many medical conditions.
Theodor Curtius was born in Duisburg in the Ruhr area in Germany. He studied chemistry with Robert Bunsen at Heidelberg University and with Hermann Kolbe at Leipzig University. He received his doctorate in 1882 at Leipzig University. After working from 1884 to 1886 for Adolf von Baeyer at the Ludwig-Maximilians-Universität München, Curtius became the director of the analytical chemistry department at University of Erlangen until 1889. Then he accepted the chair in Chemistry at Kiel University, where he remained very productive. In line with this success, Curtius was appointed Geheimer Regierungsrat (Privy Councillor) in 1895. After a one-year appointment as the successor of the famous August Kekulé at the University of Bonn in 1897, Curtius succeeded Victor Meyer as Professor of Chemistry at his old university at Heidelberg University in 1898, where he remained until his retirement in 1926. He was awarded honorary membership of the Manchester Literary and Philosophical Society in 1892 and was succeeded by Karl Freudenberg, who wrote Curtius' biography in 1962.[1] In his free time, he also composed music, sang in concerts, and was an active mountaineer. In 1894, he founded the Kiel section of the Association of German and Austrian Alpinists, which he personally supported with gifts. In his Munich period, he became a close friend of the alpinist guide Christian Klucker, with whom he made mountaineering hikes for many years thereafter. Theodor Curtius died in Heidelberg on 8 February 1928.
== Chemistry == Diazepam does not possess any chiral centers in its structure, but it does have two conformers: the 'P'-conformer and 'M'-conformer. Diazepam is an equimolar mixture, and it was shown through CD spectra in serum protein solutions that the 'P'-conformer is preferred by α1-acid glycoprotein binding. The drug diazepam occurs as a pale yellow-white crystalline powder without a distinctive smell and has a low molecular weight (MW = 284.74 g/mol). This classic aryl 1,4-benzodiazepine possesses three acceptors and no hydrogen bond donors. Diazepam is moderately lipophilic with LogP (Octanol-Water Partition Coefficient) value of 2,82 and hydrophilic with a TPSA (Topological Polar Surface Area) value of 32.7 Ų. The LogP value indicates that diazepam tends to dissolve more readily in lipid-based environments, such as chloroform, acetone, ethanol and ether, compared to water. The TPSA value implies that a segment of the molecule exhibits a degree of polarity or hydrophilicity and represents the collective surface area of polar atoms, like oxygen or nitrogen, along with their connected hydrogen atoms. A TPSA value of 32,7 Ų signifies a moderate level of polarity within the compound. TPSA is especially useful in medical chemistry as it shows the ability of a molecule to permeate cells. Molecules with a PSA value smaller than 60–70 Ų have a better ability to permeate cells.
Sources: en.wikipedia.org
After around 8 weeks customised foot orthoses can offer short-term relief. Other treatments have little supportive evidence and studies. These include rest, massage, heat, ice, and calf-strengthening exercises, weight reduction in the overweight or obese, and nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen. NSAID use is common, but fails to resolve pain in 20% of people. Corticosteroid injections are sometimes used for cases resistant to more conservative measures. Tentative evidence supports their use for short-term pain relief up to one month (only). Comparative evidence suggests that short- and long-term treatment effects vary. Corticosteroid injections may provide greater short-term pain relief, but their benefits then fade. In contrast, therapies such as platelet-rich plasma (PRP) and ESWT are associated with improved pain and functional outcomes over longer follow-up periods. However, studies remain inconsistent, and evidence quality is limited by variability in study design, treatment protocols, and outcome measures. As a result, no single treatment is established as universally superior. Another treatment technique is plantar iontophoresis. This technique involves applying anti-inflammatory substances such as dexamethasone or acetic acid topically to the foot and transmitting these substances through the skin with an electric current. Some evidence supports the use of night splints for 1–3 months to relieve pain after six months.
== Genetics == The Sar1B GTPase is an enzyme located in epithelial cells of the gastrointestinal tract. These proteins are critical for release of chylomicrons in the body. Chylomicron retention disease is an autosomal homozygous recessive disorder arising from mutations in the gene encoding the Sar1B GTPase. The Sar1B gene is located at position 5q31.1 in the fifth chromosome and is composed of eight exons. Alternative splicing of the second exon results into two different splice isoforms for the Sar1B transcript RNA. In CMRD, a mutation of this genomic sequence affects the Sar1B enzyme's ability to interact with Guanine Exchange Factors (GEFs) and GTP-Activating Proteins (GAPs). The mutation of exon 6 of the sequence can eliminate the critical chain that is responsible for recognizing guanine. This strips the GTPase of its capability to hydrolyze GTP, its hallmark trait. This overall affects the ability of Sar1B GTPase to control chylomicron release. A third mutant allele containing a missense mutation has also been reported to cause CMRD. All three of these alleles display recessive inheritance, suggesting that they loss-of-function mutations cause the symptoms of CMRD.
Strychnine was commonly used as an athletic performance enhancer and stimulant in the late 19th century and early 20th century. The best-known incident of this usage was during the 1904 Olympics marathon, when track-and-field athlete Thomas Hicks was administered a concoction of egg whites and brandy that contained strychnine by his assistants in an attempt to boost his stamina; Hicks did not know that it contained strychnine. Maximilian Theodor Buch proposed that strychnine was a cure for alcoholism. Although strychnine has no known addictive properties, in The Invisible Man (1897), H. G. Wells imagined the protagonist, Griffin, to be a strychnine addict:
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.